Subclinical Hypothyroidism (TSH 5–10 mIU/L with Normal Free T4)
Subclinical hypothyroidism with a mildly elevated TSH (5–10 mIU/L) is managed primarily with confirmation of persistence and risk-based consideration of levothyroxine versus observation. [1, 2, 3]
Diagnostic Confirmation and Etiology Assessment
Repeat TSH with free T4 is recommended to confirm persistence before treatment decisions. [1, 2] Testing for thyroid autoimmunity is recommended using anti–thyroid peroxidase (anti-TPO) antibodies when starting a management strategy. [1] Reversible or secondary contributors to TSH elevation should be assessed, including medication effects and recent illness, before labeling persistent subclinical hypothyroidism. [1, 2]
Treatment Initiation Thresholds
Levothyroxine is recommended for adults with subclinical hypothyroidism when TSH is 10 mIU/L or higher on 2 separate occasions spaced 3 months apart. [1] For adults with TSH below 10 mIU/L, levothyroxine initiation is managed by individualized clinical factors rather than reflex treatment. [1] Routine thyroid hormone therapy is not recommended for most adults with subclinical hypothyroidism, including those with TSH in the 4.5–10 mIU/L range, due to lack of meaningful clinical benefit. [2]
Medication Selection Algorithm
Levothyroxine is the thyroid hormone recommended when treatment is indicated for subclinical hypothyroidism. [1] A conservative dosing strategy is used in patients with risk of overtreatment, including older age and cardiovascular disease risk. [1]
Monotherapy Versus Combination Therapy
Levothyroxine monotherapy is recommended for subclinical hypothyroidism. [1] Combination therapy with triiodothyronine (T3) is not recommended for subclinical hypothyroidism. [1]
Key Evidence Supporting Observation
In randomized placebo-controlled trial data in older adults (TRUST; age ≥65 years) with persistent subclinical hypothyroidism, levothyroxine did not improve thyroid-related symptom scores or tiredness scores versus placebo. [3] A BMJ Rapid Recommendation concluded that thyroid hormone therapy does not provide clinically important benefits for most adults with subclinical hypothyroidism, and it should not be routinely used. [2]
Treatment Initiation in Patients With Lower TSH but Higher-Risk Features
Levothyroxine should be considered when clinical features suggest underlying thyroid disease or increased risk, including:
- Symptoms suggestive of hypothyroidism. [1]
- Elevated thyroid autoantibodies (anti-TPO positivity). [1]
- Goiter or structural thyroid disease. [1]
- Pregnancy-related indications (preconception or pregnancy) and fertility-related contexts. [1]
Targets or Goals of Therapy
When levothyroxine is used, the target is normalization of TSH into the reference range. [1]
Follow-Up and Monitoring Strategy
In untreated subclinical hypothyroidism, TSH and free T4 should be monitored periodically. [1] Annual monitoring of TSH and free T4 is recommended in patients without underlying thyroid disease, and more frequent monitoring is recommended when an underlying thyroid condition is present. [1] Reassessment for progression to overt hypothyroidism is required during follow-up. [1, 2]
Common Pitfalls to Avoid
Overtreatment should be avoided because routine therapy for mild TSH elevations is not associated with clinically meaningful benefit for most adults. [2, 3] Failure to confirm persistence with repeat testing before starting levothyroxine should be avoided because transient TSH elevation is common and treatment decisions should be based on persistent abnormalities. [1, 2]
Target Population-Specific Notes
In older adults with subclinical hypothyroidism, randomized trial data support avoidance of routine levothyroxine therapy. [2, 3] In asymptomatic adults with TSH 5–10 mIU/L and normal free T4, observation with repeat testing is the default management approach unless higher-risk features justify a trial of levothyroxine. [1, 2]